Team

Dr. Daniel Vitt

Dr Daniel Vitt ImmunicDr. Daniel Vitt is the CEO of Immunic AG. He joined Immunic from 4SC AG, a publicly listed stock 
company based in Martinsried, Germany which he co-founded in 1997. At 4SC, he served as CSO and CDO. In this position, he transformed 4SC from a research company into an advanced therapeutic development company and brought the company public on German stock exchange in Frankfurt in 2005.

As a member of the executive Board, he was responsible for all research and development activities at 4SC group including four clinical stage products. In this position, he essentially contributed to 4SC’s maturing therapeutic pipeline and succeeded in bringing several projects in the field of autoimmune diseases, oncology and infectious diseases towards development stage. Among them are 4SCs’ phase 2 products Resminostat, 4SC-202 and IMU-838.

Daniel Vitt studied chemistry in Siegen and Würzburg, Germany from 1989 – 1994 and graduated at the University of Würzburg in the group of G. Bringmann in quantum-chemical calculations of organic reactions. During his Ph.D. studies, he focused on molecular design of small molecule therapeutics. In 1998, he received his Ph.D. from the Institute of organic chemistry at the University of Würzburg.

Daniel Vitt is managing director of 4SC Discovery GmbH and member of the supervisory board of Quattro Research GmbH. He is member of the Scientific Advisory board of CI3 Cluster in Mainz.

 Download biography

Short Bio

  • SKILLS

    Entrepreneurial track record and leadership

  • QUALIFIATION

    Co-Founder of 4SC AG, managing director and board member of several companies in the life-science industry

  • Experience

    Transformation of R&D company to advanced clinical development stage and IPO on German stock exchange

  • Motivation

    Leading companies to outstanding levels of excellence

Dr. Andreas Mühler

Dr. Andreas MuehlerDr. Andreas Mühler is the CMO of Immunic AG. He received his medical degree (MD) from Humboldt-University in Berlin, Germany and an MBA degree from Duke University. After a short period in clinical work, Andreas has worked within the pharmaceutical industry since 1992, most of it in the US, with leadership positions in preclinical and clinical development, business development & licensing and marketing. During this period, Andreas was involved in several clinical programs and regulatory submissions (IND, NDA) as well as several large licensing deals.

Since 2003, Andreas developed and managed multiple medical companies in the US. Among them were 3TP LLC d/b/a CAD Sciences (White Plains, NY), a medical software company developing an imaging solution for early detection of breast and prostate cancer, which was subsequently sold to iCAD Medical in 2008. Another startup was Cellectar Inc. (Madison, WI), a biotech company developing new cancer therapeutics and cancer imaging agents, in which Andreas managed the initial development of the lead compound until IND filing.

Andreas was also President & CEO of MicroMRI Inc (Langhorne, PA), a medical device company developing solutions for improved osteoporosis diagnosis and therapy monitoring based on bone micro-architecture. He has been on the Board of Directors of multiple small medical technology companies.

After moving to Munich in 2009, Andreas became Managing Director of the small healthcare private equity fund Palladius Healthcare GmbH (Munich, Germany) which acquired distressed medical technology companies. As part of this fund, Andreas was involved in the management of portfolio companies.

Thereafter, Andreas worked as interim manager and has been doing multiple interim management projects for pharmaceutical and medical device companies. Most of these assignments involved managing large clinical trials in the oncology area. Additionally, Andreas was also closely involved in the launch of several major pharmaceuticals in Germany, among them Brentuximabvedotin (for treatment of Hodgkin lymphoma and some NHL), Vedolizumab (an antibody for treatment of inflammatory bowel disease) and an oral budesonide as treatment for ulcerative colitis.

Download biography

 

Short Bio

  • SKILLS

    Within the pharmaceutical industry since 1992

  • QUALIFICATION

    Developed and managed multiple medical companies in the US and Germany

  • Experience

    Did multiple interim management positions for pharmaceutical and medical device companies

  • Motivation

    Developing innovative therapies for patients with debilitating diseases

Dr. Manfred Gröppel

Dr. Manfred Gröppel

Dr. Manfred Gröppel is the COO of Immunic AG. While working three years at the Research Center Siemens, Dr. Gröppel received his Doctorate in chemistry from the Institute of Organic Chemistry, University Erlangen-Nuremberg, Germany.

In his role as Head of Business Development at 4SC AG, Manfred managed worldwide business development activities since 2001. Manfred has been part of the development team since 2002 and served as project leader for the autoimmune project IMU-838. Prior to joining 4SC, Manfred hold various positions at Tripos Inc., covering business development activities in Central and South Europe, Scandinavia and Israel.

Manfred is an experienced business development professional with a track record of successful licensing transactions in the healthcare industry worldwide (EU, USA, Japan). He has more than 18 years of BD/L leadership experience with a strong scientific background and sound knowledge in drug discovery, product development, manufacturing processes, CMC, patents, clinical trial design, regulatory and project valuation.

Manfred has established a worldwide network including USA, Japan, Korea and China and was involved in several deals worth more than 500 Mio. USD including Menarini, Yakult Honsha, Link Health, Nycomed, Serono, Schwarz Pharma, Sanofi-Aventis, Boehringer Ingelheim, Schering, Astra Zeneca, Recordati and Esteve.

Amongst other successful transactions, major achievements include:

  • Out-licensing of APAC rights of Resminostat (phase 2) to Menarini in a deal worth up to 95 Mio. EUR plus double-digit royalties
  • Out-licensing of Japanese rights of Resminostat (phase 2) to Yakult Honsha in a deal worth more than 192 Mio. USD plus royalties, featured on the front page of BioWorld in April 2011
  • Successfully in-licensed 8 projects, clinical and pre-clinical stage, for 14 Mio. EUR in a one-time payment without further milestones and royalties
  • In charge of finding a new home for an innovative project into a spin-off company in the USA.

Manfred has been invited speaker at several national and international conferences and is owner of several patents and co-author of scientific publications.

Download biography

Short Bio

  • SKILLS

    Drug discovery, product development, patents, etc.

  • QUALIFIATION

    Doctorate in chemistry

  • Experience

    Worldwide business development
    since 2001

  • Motivation

    Pushing business development to a new level.

Dr. Hella Kohlhof

Dr. Hella Kohlhof is the CSO of Immunic AG and Managing Director of Immunic’s research subsidiary, Immunic Research GmbH, Halle (Saale). She joined Immunic in January 2017 from 4SC AG, a publicly listed German biotech company where she was responsible for the management of the clinical product portfolio.

Hella Kohlhof studied biology in Aachen, Gothenburg (Sweden) and Munich and received her Doctorate in Biology from the Ludwig Maximilians University of Munich (Germany). During her Ph.D. and PostDoc position at the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich, she worked on normal and malignant B cell development influenced by Notch and Epstein Barr Virus mediated signaling.

In 2008, she joined 4SC AG as a research scientist and group leader and established the research laboratory for translational pharmacology. She worked on 4SC’s preclinical and clinical stage projects in the oncology and immunology field, including IMU-838 and IMU-935. From 2011 on, Hella was responsible for the management and development of 4SC’s epigenetic clinical stage small molecule inhibitor 4SC-202.

In early 2015, as Director Development Projects, she took over responsibility for the complete development portfolio of 4SC AG. Hella has a very strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational pharmacology, clinical trial design and biomarker development.

She has been invited speaker at international conferences and is owner of several patents and co-author of a book chapter and several scientific publications.

Download biography

Short Bio

  • SKILLS

    Transition of preclinical to clinical stage products

  • QUALIFIATION

    Experienced in preclinical research up to managing the development portfolio at 4SC

  • Experience

    Drug development, preclinical and translational pharmacology, clinical trial design, biomarker development

  • Motivation

    Developing state-of-the-art treatments of autoimmune diseases